Genelux Corporation

The tail end of the year is often a weak period for biotech flotations, so perhaps the fact that the companies that went public in Q4 of 2023 managed to raise more than those in either Q1 or Q2 is a h

The market for initial public offerings by biopharmaceutical companies declined to just 22 IPOs in the US in 2022 and it has gotten off to a slow start in 2023 with just three small offerings to date,

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OliX, Hansoh Ink Licensing Pact To Deve

Artificial intelligence and machine learning have moved from buzzwords to long-term business strategies in biopharmaceutical drug development with hundreds of millions of dollars invested in individua